# Kinetics of Degradation of Levothyroxine in Aqueous Solution and in Solid State

## Chong Min Won<sup>1</sup>

Received January 23, 1991; accepted August 27, 1991

The kinetics of the deiodination of levothyroxine in aqueous solution were studied over the pH range 1 to 12. Temperature dependence of the reaction was also studied. The  $\log k$  pH profile indicated that the kinetics of deiodination include proton attack on the anion and dianion in acidic solution and water attack on the anion and dianion in alkaline solution. A possible mechanism of the deiodination was discussed. The solid-state stability of levothyroxine sodium was studied at elevated temperatures; and the compound was found to undergo deamination on heating. The decomposition follows biphasic first-order kinetics, with the most rapid decomposition occurring at the beginning of heating.

**KEY WORDS:** levothyroxine; liothyronine; degradation, deiodination; pH effect; solid-state stability.

## INTRODUCTION

Levothyroxine sodium is the sodium salt of the levoisomer of thyroxine  $(T_4)$ , an active physiological compound found in the thyroid gland. Preparations of the synthetic hormone are indicated in replacement or supplemental therapy for patients with hypothyroidism and as pituitary thyroid stimulating hormone suppressants in the treatment of euthyroid goiters (1).

Deiodination occurs as a result of ultraviolet irradiation in aqueous media, and the deiodination process was proportional to the decrease in the pH of the aqueous solution (2). When  $T_4$  labeled with  $^{131}I$  was administered intravenously to normal humans, most labeled iodine eventually appeared in the urine as free inorganic iodide (3). The possible physiological significance of the deiodination of the thyroid hormone caused many investigators to study the process both *in vitro* and *in vivo*. The deiodination of  $T_4$  occurred in kidney, brain, liver, and muscle homogenate preparations. There was, however, only limited evidence for liothyronine  $(T_3)$  formation (4).

Despite a long history of its use, the *in vitro* degradation studies of  $T_4$  appearing in the above literature were of descriptive nature, providing limited kinetic information. The purpose of this study was to obtain kinetic data on the degradation of  $T_4$  in solution and in solid state and to investigate possible mechanisms of the degradation processes. This study was not intended to predict the *in vivo* transformation of the drug.

#### MATERIALS AND METHODS

#### Materials

Levothyroxine sodium and liothyronine were obtained from Biochemie (Austria) and Aldrich Chemical (Milwaukee, WI), respectively. Water used for kinetics was deionized and distilled. Acetonitrile used was HPLC grade. All the chemicals used were reagent grade and were used as received. TLC plates were obtained from Analtech (Newark, DE).

## **HPLC Analysis**

The chromatography system consisted of an isocratic pump (Beckman Model 110A), an automatic injector (IBM LC/9504), a variable-wavelength UV detector (LDC Spectromonitor III), and a computing integrator (Hitachi D-2000). The HPLC method employed a 250  $\times$  4.6-mm-i.d., 5- $\mu$ m-particle size, cyano-bonded silica column (Phenomenex) and a mobile phase consisting of water:acetonitrile:phosphoric acid (600:400:1, v/v). The flow rate was 1.5 ml/min and the detector wavelength for ultraviolet absorbance detection was 225 nm.

## Solution Degradation Product

Approximately 500 mg of levothyroxine sodium was dissolved in 70 ml of 0.01 N NaOH and refluxed for 40 hr. The solution was then neutralized by adding concentrated HCl dropwise and evaporated to dryness using a rotary evaporator. The residue was extracted with 50 ml of acetonitrile. The acetonitrile solution was concentrated, streaked across a 1-mm-thick silica gel GF preparative TLC plate, and developed with a solvent system consisting of methylene chloride: acetonitrile:formic acid (80:10:10). Using the TLC system, a  $T_4$  spot showed at  $R_f$  0.27 and a major degradate spot at  $R_f$ 0.18. The band corresponding to  $R_f$  0.18 was removed from the plate and eluted with 50 ml of 0.01 N methanolic NaOH solution. The eluent was acidified by adding concentrated HCl dropwise and the resultant precipitate was centrifuged. The supernatant was decanted and the solid was dried under vacuum at 60°C for 2 hr.

The electron impact mass spectrum of the degradate was run on a VG 7070 SE mass spectrometer. The spectrum was obtained at 70 eV with the source temperature at 190°C. The low-resolution mass spectrum exhibited a protonated molecular ion at m/z 651 corresponding to  $C_{15}H_{12}I_3NO_4$ , loss of water (m/z 633), and loss of carbon dioxide (m/z 607). The proton NMR spectrum of the isolated degradate was recorded on a Varian VXR 200 NMR spectrometer using deuterated DMSO as the solvent. The proton NMR spectrum of the degradate showed a doublet (6.91 and 6.95 ppm) corresponding to the hydrogen atom which had replaced iodine at either the 3' or the 5' carbon, a doublet (7.02 and 7.03 ppm), and a quadruplet (6.60, 6.62, 6.65 and 6.66 ppm), corresponding to the hydrogens at 2' and 6' carbons. The MS and NMR spectra were identical to those of authentic  $T_3$ . The major degradation peak seen in an HPLC chromatogram of T<sub>4</sub> which had been partially degraded in acidic solution had a retention time identical to that of authentic T<sub>3</sub>. The coin-

<sup>&</sup>lt;sup>1</sup> Analytical and Physical Chemistry Department, Rhône-Poulenc Rorer Central Research, 500 Virginia Drive, Building No. 5, Fort Washington, Pennsylvania 19034.

Won

jection of an acid-degraded  $T_4$  with authentic  $T_3$  resulted in one peak (chromatogram not shown).

#### Solid-State Degradation Products

Approximately 500 mg of levothyroxine sodium in an open vial was kept in an oven at 60°C for 7 weeks. The degraded levothyroxine sodium was suspended in 150 ml of a methanol and water mixture (30:70). The sample was completely dissolved by dropwise addition of conc. NH<sub>4</sub>OH and subsequently acidified by dropwise addition of conc. HCl. The resultant precipitate was filtered, dissolved in methanol, streaked across a 1-mm-thick silica gel GF plate, and developed with a solvent system consisting of toluene:ethylacetate:acetic acid (75:22:3). Using the TLC system, a T<sub>4</sub> spot showed at  $R_f$  0.05 and two major degradate spots at  $R_f$  0.89 and 0.06. The bands corresponding to  $R_f$  0.89 and  $R_f$  0.60 were separately removed from the plate and eluted with methanol. The eluent was evaporated to dryness and the residue was dried at 60°C for 2 hr under vacuum. Highresolution EI-MS of the  $R_f$  0.89 product showed a molecular ion at m/z 717.6488 corresponding to  $C_{13}H_6O_3I_4$  (calculated m/z 717.6494) and ions resulting from the two subsequent losses of iodine (m/z) 591 + H, 464). The other product  $(R_A)$ 0.60) showed a protonated molecular ion at m/z 760.6638 corresponding to  $C_{15}H_9I_4O_4$  (calculated m/z 760.6677) and ions resulting from loss of water (m/z) 742) and loss of carbon dioxide (m/z 716).

## Solubility-pH Profile

The solubility of levothyroxine sodium in aqueous buffer solution was determined as a function of pH ranging from 1 to 11. The buffers used were glycine (pH 1.0–3.7), acetate (pH 4.5–4.7), phosphate (pH 5.8–8.0), and carbonate (pH 9.3–11.0) buffers. The ionic strength was adjusted to 0.5. An excess amount of levothyroxine sodium was placed in a screw-cap test tube containing the aqueous buffer solutions. The solution was shaken at 25°C on a rotary shaker until replicate analyses of the solution sampled at 4-hr intervals indicated that a steady concentration had been reached. Eighteen hours of shaking sufficed for the equilibration. The undissolved solid was then separated by centrifugation. The pH of the solution was measured, and after appropriate dilutions with the mobile phase, the solution was analyzed by HPLC.

## Kinetic Method

The buffers used for kinetics were citrate (pH 3.2), acetate (pH 4.4–5.4), phosphate (pH 6.3–7.0), borate (pH 8.8), and carbonate (pH 9.6–10.7) buffers. Buffer stock solutions of 0.2 M were prepared. Aliquots of the buffer stock solutions and 1 M NaCl solution were diluted so that the final total buffer concentration was 0.02 M and the ionic strength was at 0.1. Low buffer concentrations were used to minimize the possible general acid–base catalysis by the buffer species. The pH of each solution was measured at the reaction temperature. For strongly acidic and basic solutions, aqueous HCl or NaOH solutions were used to obtain the desired pH. The pH values of these solutions at the reaction temperatures were calculated from the published activity coef-

ficients (5). In a typical kinetic experiment, 0.5 ml of 1 mg/ml levothyroxine sodium stock solution in methanol, an appropriate amount of buffer stock solution, HCl or NaOH, and an appropriate amount of 1 M NaCl were transferred into a 100-ml volumetric flask and filled to volume with water. The final concentration of levothyroxine sodium was 5  $\mu$ g/ml. The reaction flask was kept in a constant-temperature water bath at 50.0, 60.0, 70.0, and 80.0°C ( $\pm$ 0.5°C). Aliquots of the sample were taken at appropriate time intervals and analyzed by HPLC.

#### RESULTS AND DISCUSSION

## Solubility-pH Profile

T<sub>4</sub> has three ionizable moieties and it can exist as the cation (C), zwitterion (Z), anion (A), and dianion (DA), depending on the pH of the solution (Scheme I). The solubility-pH profile (Fig. 1) was used to determine the ionization con-




Fig. 1. Plot of logarithm of solubility of T<sub>4</sub> as a function of pH at 25°C.

stants (6). The equation for the solubility (S) of T<sub>4</sub> as a function of hydrogen ion activity up to pH 9.8 is given by

$$S = S_o (1 + [H^+]/K_{a1} + K_{a2}/[H^+])$$
 (1)

where  $S_o$  is the intrinsic solubility of Z. The value of  $S_o$  (0.25 µg/ml) was estimated from the best fit of the solubility–pH profile between pH 3 and pH 6. The p $K_a$  values that gave the best fit to Eq. (1) are p $K_{a1} = 2.40$  for the carboxyl group and p $K_{a2} = 6.87$  for the phenolic OH group. The solubility–pH profile shows a break around pH 10 indicating a saturation

solubility of A. As the pH increases above 10, the solubility increases as more DA is formed, in accordance with

$$S = S_o + S_o' (1 + K_{a3}/[H^+])$$
 (2)

where  $S_{\rm o}'$  is the maximum solubility of A. The  $S_{\rm o}'$  (120 µg/ml) and p $K_{\rm a3}$  (9.96) values were estimated from the best fit of the solubility-pH profile above pH 10. The p $K_{\rm a}$  values determined under these conditions are slightly different from the published values of 2.2 for the carboxyl group, 6.7 for the phenolic group, and 10.1 for the amino group (7).




Fig. 2. Typical first-order plots for the deiodination of  $T_4$  in aqueous solution at 80°C. pH 2.05 ( $\blacksquare$ ); pH 6.86 ( $\bullet$ ); pH 7.96 ( $\triangle$ ); pH 10.55 ( $\blacklozenge$ ).

134 Won




Fig. 3.  $\log k$  - pH profiles for the degradation of  $T_4$  in aqueous solution at 50°C ( $\Diamond$ ), 60°C ( $\triangle$ ), 70°C  $\square$ ), and 80°C ( $\bigcirc$ ) and of T<sub>3</sub> at 80°C (●).

## Log k - pH Profile

For all the kinetic experiments, the first-order plots for loss of T<sub>4</sub> were linear (correlation coefficient >0.998) for two or more half-lives. Typical first-order plots are shown in Fig. 2. The  $\log k$  - pH profiles for the deiodination of  $T_4$  are shown in Fig. 3. The rate of deiodination shows a plateau in the acidic pH region, drops off sigmoidally in the neutral pH region, and shows another plateau in the alkaline pH region. The  $\log k$  - pH profile shows a sigmoidal change only when the phenolic OH group is ionized (p $K_{a2} = 6.87$ ). No change was observed when the carboxyl group  $(pK_{a1} = 2.40)$  or

Table I. Catalytic Rate Constants, Arrhenius Parameters, and Entropies of Activation for Deiodination of T4

Temperature (°C)	$ k_{\rm H} \atop (\sec^{-1} M^{-1}) $	$10^8 k_{o}'$ (sec <sup>-1</sup> )
$80.0 \pm 0.5$	14.3	34.3
$70.0 \pm 0.5$	7.00	20.8
$60.0 \pm 0.5$	3.16	13.0
$50.0 \pm 0.5$	1.56	6.95
$25.0^{c}$	0.165	1.36
$E_a$ (kcal · mol <sup>-1</sup> )	16.8	12.1
$\log A$	11.5	1.0
$\Delta S^{\ddagger}$ (cal, mol <sup>-1</sup> K <sup>-1</sup> )	-7.8	~55.9




Fig. 4. Typical HPLC chromatograms of partially degraded samples. (a) T<sub>4</sub> in acidic solution. (b) T<sub>4</sub> in alkaline solution. (c) T<sub>3</sub> in acidic solution. (d) T<sub>3</sub> in alkaline solution. T<sub>4</sub> (A); T<sub>3</sub> (B); T<sub>2</sub> (C); unknown (D).

amino group (p $K_{a3} = 9.96$ ) was ionized. The carboxyl and amino groups are too far away from the reaction center so that the ionization of these groups appears to have little resonance or inductive effect on the deiodination rate.

As shown in the  $\log k$  – pH profile, the rate constant does not increase with increasing acidity in the strongly acidic region, indicating that there is no contribution to the rate constant from the proton attack on C and Z. The overall deiodination of T4 can be explained by spontaneous or water-catalyzed reactions  $(k_0)$  of C and Z and spontaneous or water-catalyzed reactions  $(k_0)$  of A and DA. The deiodination rate constant can be formulated as

$$k = k_{\rm o} f_{\rm HA} + k_{\rm o}' f_{\rm A} \tag{3}$$

where  $f_{HA}$  and  $f_A$  are the sum of the fractions of C and Z and of A and DA, respectively. Equation (3) is kinetically equivalent to

$$k = k_{\rm H} [{\rm H}^+] f_{\rm A} + k_{\rm o}' f_{\rm A}$$
 (4)

where  $k_0 = k_H K_{a2}$  and  $k_H$  is the catalytic rate constant for proton attack on A and DA. Substituting  $f_A = K_{a2}/([H^+] +$  $K_{a2}$ ) in Eq. (4),

$$CH_{2}-CH-COOH \qquad (T_{4})$$

$$CH_{2}-CH-COOH \qquad (T_{4})$$

$$CH_{2}-CH-COOH \qquad (T_{4})$$

$$CH_{2}-CH-COOH \qquad (T_{5})$$

$$CH_{2}-CH-COOH \qquad (T_{5})$$

$$CH_{2}-CH-COOH \qquad (T_{5})$$

Scheme II

<sup>&</sup>lt;sup>a</sup> Where  $k = k_{\rm H} [{\rm H}^+] f_{\rm A} + k_{\rm o}' f_{\rm A}$ . <sup>b</sup> Where  $\log k = -E_{\rm a}/2.303 \ {\rm RT} + \log A$ .

<sup>&</sup>lt;sup>c</sup> Extrapolated from  $E_a$  and log A.

$$k = K_{a2} (k_H [H^+] + k_o')/([H^+] + K_{a2})$$
 (5)

In the acidic pH region,  $[H^+] \gg K_{a2}$ , and Eq. (5) reduces to

$$k = k_{\rm H} K_{\rm a2} \tag{6}$$

In the alkaline pH region,  $[H^+] \ll K_{a2}$ , and Eq. (5) reduces to

$$k = k_0' \tag{7}$$

The catalytic rate constants,  $k_{\rm H}$  and  $k_{\rm o}'$ , were estimated from the best fit of the log  $k-{\rm pH}$  profiles (Table I). The Arrhenius parameters of the rate constants are included in Table I.

## Mechanism of Deiodination

The HPLC chromatogram (Fig. 4a) of  $T_4$  partially degraded in acidic solution contains a peak with a retention time corresponding to that of  $T_3$ . The HPLC chromatogram (Fig. 4b) of  $T_4$  partially degraded in alkaline solution contains a peak with a retention time of 4.0 min (Peak D) of an unknown degradate but no peak corresponding to that of  $T_3$ . When the initial concentration of  $T_4$  was increased above 5 mg/ml in alkaline degradation,  $T_3$  was found to be the major degradate. The chromatogram (Fig. 4c) of  $T_3$  partially degraded in acidic solution contains a peak with a retention time corresponding to that of 3,5-diiodothyronine ( $T_2$ ). The chromatogram (Fig. 4d) of  $T_3$  partially degraded in alkaline solution contains Peak D.

When degraded under the same conditions as  $T_4$  at 80°C,  $T_3$  was found to be more stable than  $T_4$  in acidic solution and less stable in alkaline solution (Fig. 3). In alkaline solution, because  $T_3$  was found to be less stable than  $T_4$  and because  $T_3$  was the major degradate at higher  $T_4$  concentration, it can be assumed that  $T_4$  degrades to  $T_3$  and  $T_3$  degrades further to the unknown degradate (Peak D) as soon as it is produced. At higher  $T_4$  concentrations, the high concentration of free iodonium ion in solution may play an important role in the deiodination rate (8). At higher iodonium ion concentrations, the deiodination may follow a different rate law, and  $T_3$  may become relatively stable.

The usual mechanism of the iodination of phenol is a two-step process involving an addition of an iodonium ion to the carbon, followed by a loss of the hydrogen atom being replaced (9). According to the principle of microscopic reversibility, the reverse sequence of these steps constitutes the favored mechanism for the reverse reaction, deiodination.

Among the four iodines in the  $T_4$  molecule, those at the 3' and 5' positions are more labile than those at the 3 and 5 positions (3). The substituted phenoxide ion moiety gives 3' and 5' carbons carbanionic character by resonance so that these carbons are favored for electrophilic attack by proton or other electrophiles (Scheme II).

Even though Eqs. (3) and (4) are kinetically equivalent, they imply different mechanisms for  $T_4$  deiodination. A simple pH dependency study does not allow differentiation of the two equations and the possible mechanisms consistent with these equations. However, because a proton should be a far more powerful electrophile than water and because the substituted phenoxide ion should be vastly more reactive than the substituted phenol, it is very likely that the proton-

ation is due to proton attack on the anion and dianion in acidic solution rather than water attack on the cation and zwitterion. The protonation in alkaline solution may be due to water attack on the anion and dianion. Therefore, the reaction scheme consistent with Eq. (4) is a more likely mechanism than that defined by Eq. (3).

## Solid-State Degradation

Low assay values are a concern of most manufacturers of levothyroxine sodium products, and in all probability, it might be attributable to solid-state instability of the drug substance (10).

In contrast to its solution degradation, levothyroxine sodium does not deiodinate in solid state. Rather, the isolated degradation products indicate a deamination reaction (Scheme III). Plots showing the rates of solid-state degradation are presented in Fig. 5. The solid-state degradation exhibited biphasic first-order degradation profiles indicating the possibility of complex degradation pathways. Correlation coefficients of no less than 0.994 were obtained for linear portions of the first-order plots. The initial rate of degradation is much greater than that obtained in the later part of the degradation curve at all temperatures. The rapid degradation phase is more pronounced at higher temperatures. As the temperature is lowered, the initial phase becomes shorter compared to the later phase. The initial phase is almost nonexistent at 50°C. It appears that there is a threshold temperature between 50 and 60°C where levothyroxine sodium degrades rapidly. The biphasic degradation kinetics of levothyroxine sodium can be described by

$$D = D_o (A e^{-k_0 t} + B e^{-k_0 t})$$
 (8)

Table II. First-Order Rate Constant for Degradation of  $T_4$  in Solid State in Accordance with  $D = D_0 (A e^{-k_3 t} + B e^{-k_5 t})$ 

Temperature (°C)	$10^6 k_a (sec^{-1})$	$10^7 k_{\rm b} ({\rm sec}^{-1})$
50 ± 2	<u> </u>	
$60 \pm 2$	_	1.71
$70 \pm 2$	_	3.97
$80 \pm 2$	7.19	7.47

136 Won




Fig. 5. Solid-state degradation of levothyroxine sodium at 50°C (♠), 60°C (♠), 70°C (♠), and 80°C (■).

where  $D_{\rm o}$  and D are the drug amounts of levothyroxine sodium at time 0 and t, respectively, A and  $k_{\rm a}$  are the intercept and slope of the rapid phase, and B and  $k_{\rm b}$  are the intercept and slope of the slow phase. For practical purposes, the  $k_{\rm a}$  value in the rapid phase is more critical than the  $k_{\rm b}$  value in the slow phase, since the former contributes more to the first 10%  $T_4$  loss. Unfortunately, it was not possible to determine the initial rate of degradation at lower temperatures with reasonable accuracy, because the initial rapid degradation phase is shorter at lower temperatures. The first-order rate constants obtained by feathering (10) are listed in Table II.

The initial degradation rate at 80°C is approximately 10 times faster than that of the later phase.

## **ACKNOWLEDGMENTS**

The author thanks Ms. C. Strohbeck for NMR spectra, Dr. S. Kelly and Mr. J. deKanel for mass spectral analysis, and Dr. C. Obetz for helpful comments.

## REFERENCES

E. R. Barnhart. Physicians' Desk Reference, Medical Economics, Oradell, NJ, 1989, pp. 1830–1831.

- A. L. Reviczky and S. B. Nagy. Untersuchung der Thyroxindejodisation mit instrumenteller analytischer Methode. *Endokri*nologie 56:81-91 (1970).
- 3. J. B. Stanbury. Deiodination of the iodinated amino acids. *Ann. N.Y. Acad. Sci.* 86 (Part 2):417–439 (1960).
- T. Jolin, G. Morreale de Escobar, and F. Escobar del Rey. Pitfalls in studies of in vitro deiodination of thyroxine. *Endocrinology* 78:7–15 (1966).
- H. S. Harned and B. B. Owen. The Physical Chemistry of Electrolyte Solutions, Reinhold, New York, 1958, p. 716.
- B. H. Lippold and J. F. Lichey. Löslichkeits-pH Profile mehrprotoniger Arzneistoffe am Beispiel des assoziierenden Dimetindens und des zwitterionischen Liothyronines. Arch. Pharm. (Weinheim) 314:541-556 (1981).
- 7. A. Post and R. J. Warren. Sodium levothyroxine. In K. Florey

- (ed.), Analytical Profiles of Drug Substances, Vol. 5, Academic Press, New York, 1976, pp. 226–281.
- E. Grovenstein, Jr., and N. S. Aprahamian. Aromatic Halogenation. II. Kinetics and mechanism of iodination of 4-nitrophenol and 4-nitrophenol-2,6-d<sub>2</sub>. J. Am. Chem. Soc. 84:212-220 (1962).
- 9. J. Hine. *Physical Organic Chemistry*, McGraw-Hill, New York, 1962, p. 358.
- J. F. Brower, D. Y. Toler, and J. C. Reepmeyer. Determination of sodium levothyroxine in bulk, tablet, and injection formulations by high-performance liquid chromatography. J. Pharm. Sci. 73:1315-1317 (1984).
- 11. A. A. Frost and R. G. Pearson. Kinetics and Mechanism, Wiley, New York, 1961, pp. 162-164.